Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer

BACKGROUND: TAS-102 plus bevacizumab is an anticipated combination regimen for patients who have metastatic colorectal cancer. However, evidence supporting its use for this indication is limited. We compared the cost-effectiveness of TAS-102 plus bevacizumab combination therapy with TAS-102 monother...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Gastroenterol
Auteurs principaux: Sugiura, Kiyoaki, Seo, Yuki, Takahashi, Takayuki, Tokura, Hideyuki, Ito, Yasuhiro, Tanaka, Motomu, Kishida, Norihiro, Nishi, Yusuke, Onishi, Yoshihiko, Aoki, Hikaru
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2021
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058969/
https://ncbi.nlm.nih.gov/pubmed/33879100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12876-021-01771-z
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires